DK2922828T3 - 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer - Google Patents
4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer Download PDFInfo
- Publication number
- DK2922828T3 DK2922828T3 DK13857326.6T DK13857326T DK2922828T3 DK 2922828 T3 DK2922828 T3 DK 2922828T3 DK 13857326 T DK13857326 T DK 13857326T DK 2922828 T3 DK2922828 T3 DK 2922828T3
- Authority
- DK
- Denmark
- Prior art keywords
- bmi
- diamino
- inhibitors
- treat cancer
- pyrimidine derivatives
- Prior art date
Links
- 101100058548 Felis catus BMI1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728907P | 2012-11-21 | 2012-11-21 | |
| PCT/US2013/071132 WO2014081906A2 (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2922828T3 true DK2922828T3 (da) | 2020-08-31 |
Family
ID=50776672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13857326.6T DK2922828T3 (da) | 2012-11-21 | 2013-11-21 | 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10428050B2 (OSRAM) |
| EP (1) | EP2922828B1 (OSRAM) |
| JP (3) | JP6412503B2 (OSRAM) |
| KR (4) | KR102275676B1 (OSRAM) |
| CN (2) | CN111423417B (OSRAM) |
| AR (1) | AR093579A1 (OSRAM) |
| AU (1) | AU2013348009C1 (OSRAM) |
| BR (1) | BR112015011760B1 (OSRAM) |
| CA (1) | CA2892045C (OSRAM) |
| CL (1) | CL2015001377A1 (OSRAM) |
| CR (1) | CR20150294A (OSRAM) |
| CU (1) | CU24387B1 (OSRAM) |
| DK (1) | DK2922828T3 (OSRAM) |
| EA (2) | EA035349B1 (OSRAM) |
| EC (1) | ECSP15019948A (OSRAM) |
| ES (1) | ES2821529T3 (OSRAM) |
| HK (1) | HK1215032A1 (OSRAM) |
| IL (2) | IL238871B (OSRAM) |
| MA (1) | MA38208B1 (OSRAM) |
| MX (2) | MX385385B (OSRAM) |
| NI (1) | NI201500072A (OSRAM) |
| NZ (2) | NZ708909A (OSRAM) |
| PE (1) | PE20151413A1 (OSRAM) |
| PH (1) | PH12015501130B1 (OSRAM) |
| PL (1) | PL2922828T3 (OSRAM) |
| PT (1) | PT2922828T (OSRAM) |
| SA (1) | SA517381847B1 (OSRAM) |
| SG (2) | SG11201503982XA (OSRAM) |
| TW (1) | TWI623531B (OSRAM) |
| UA (1) | UA118094C2 (OSRAM) |
| WO (1) | WO2014081906A2 (OSRAM) |
| ZA (1) | ZA201503642B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI623531B (zh) * | 2012-11-21 | 2018-05-11 | Ｐｔｃ治療公司 | 經取代反向嘧啶ｂｍｉ－１抑制劑 |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA2917671A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| JP6524094B2 (ja) * | 2013-08-30 | 2019-06-05 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換ピリミジンＢｍｉ−１阻害剤 |
| US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| EP3335126A4 (en) | 2015-08-11 | 2019-05-01 | Cognoa, Inc. | METHOD AND DEVICE FOR DETERMINING DEVELOPMENT PROGRESS WITH ARTIFICIAL INTELLIGENCE AND USER ENTRY |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| US20190016680A1 (en) * | 2016-01-14 | 2019-01-17 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| CN110192252A (zh) | 2016-11-14 | 2019-08-30 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| EP3580700A4 (en) * | 2017-02-09 | 2020-11-18 | Cognoa, Inc. | PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE |
| KR20200035292A (ko) | 2017-08-01 | 2020-04-02 | 피티씨 테라퓨틱스, 인크. | 혈액 암 치료에 사용하기 위한 dhodh 억제제 |
| EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| US12023335B2 (en) * | 2018-08-17 | 2024-07-02 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| CN109988172B (zh) * | 2019-01-10 | 2020-09-29 | 石家庄学院 | 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法 |
| EP3911418A1 (en) * | 2019-01-15 | 2021-11-24 | PTC Therapeutics, Inc. | Method for treating an acute myeloid leukemia |
| WO2020176610A1 (en) * | 2019-02-28 | 2020-09-03 | Ptc Therapeutics, Inc. | Method for treating a multiple myeloma |
| US20220185795A1 (en) * | 2019-03-11 | 2022-06-16 | Ptc Therapeutics, Inc. | Compound form having enhanced bioavailability and formulations thereof |
| KR102785528B1 (ko) | 2019-03-22 | 2025-03-21 | 코그노아, 인크. | 개인 맞춤식 디지털 치료 방법 및 디바이스 |
| BR112021019170A2 (pt) * | 2019-03-27 | 2022-03-03 | Ptc Therapeutics Inc | Combinações úteis em um método para tratar sarcoma |
| BR112021019508A2 (pt) * | 2019-04-02 | 2022-02-01 | Hinova Pharmaceuticals Inc | Composto de amina aromática e uso do mesmo na preparação de reguladores e inibidores duplos de ar e brd4 |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (OSRAM) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| CN1102144C (zh) | 1994-08-13 | 2003-02-26 | 株式会社柳韩洋行 | 新的嘧啶衍生物及其制备方法 |
| IN188411B (OSRAM) | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| KR100272471B1 (ko) | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| ATE253915T1 (de) | 1999-06-30 | 2003-11-15 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| CA2386218A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| EP1224185B1 (en) | 1999-10-27 | 2005-11-30 | Novartis AG | Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use |
| CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
| AU4262901A (en) | 2000-03-29 | 2001-10-08 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DE60136731D1 (de) | 2000-09-20 | 2009-01-08 | Ortho Mcneil Pharm Inc | Pyrazine derivate als tyrosin kinase modulatoren |
| AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| EP1377573B1 (en) | 2000-12-15 | 2005-07-27 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| CN100415744C (zh) | 2001-02-20 | 2008-09-03 | 阿斯特拉曾尼卡有限公司 | 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶 |
| EP1364212B1 (en) * | 2001-03-02 | 2011-02-02 | GPC Biotech AG | Three hybrid assay system |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| ATE337312T1 (de) | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| WO2003011837A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2003212634A1 (en) * | 2002-03-11 | 2003-09-22 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| WO2003099811A1 (en) | 2002-05-23 | 2003-12-04 | Cytopia Pty Ltd | Kinase inhibitors |
| AU2003246100A1 (en) | 2002-06-28 | 2004-01-19 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004007407A2 (en) * | 2002-07-11 | 2004-01-22 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
| US20040110821A1 (en) | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| EP1551842A1 (en) | 2002-10-15 | 2005-07-13 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| GB2432834A (en) | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| EP1713793A4 (en) | 2004-02-04 | 2009-09-02 | Smithkline Beecham Corp | PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS |
| EP2332940B1 (en) | 2004-03-30 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| JP2006045119A (ja) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| AU2006219231B2 (en) | 2005-02-28 | 2010-01-14 | Japan Tobacco Inc. | Novel aminopyridine compound with Syk inhibitory activity |
| US20110098301A1 (en) | 2005-03-10 | 2011-04-28 | Bayer Healthcare Llc | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders |
| BRPI0713328A2 (pt) | 2006-06-22 | 2012-10-30 | Biovitrum Ab | derivados de piridina e pirazina como inibidores de cinase mnk |
| CN101516873A (zh) | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| AU2007304195A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| CN101679432B (zh) | 2006-10-19 | 2015-04-22 | 西格诺药品有限公司 | 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途 |
| BRPI0720635A2 (pt) | 2006-12-22 | 2014-01-07 | Novartis Ag | Compostos orgânicos e seus usos |
| TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| GB0714573D0 (en) | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
| EP2203436A1 (en) | 2007-09-17 | 2010-07-07 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| WO2009064835A1 (en) | 2007-11-16 | 2009-05-22 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| ATE524459T1 (de) | 2007-12-07 | 2011-09-15 | Novartis Ag | Pyrazolederivate und ihr einsatz als hemmer von cyclinabhängigen kinasen |
| DE102008005493A1 (de) | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
| GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| EP2306836B1 (en) * | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
| CA2731368C (en) | 2008-08-06 | 2013-05-14 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| CN102177154A (zh) * | 2008-09-02 | 2011-09-07 | 神经研究公司 | 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用 |
| TW201028399A (en) * | 2008-11-27 | 2010-08-01 | Shionogi & Co | Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity |
| MX2011008444A (es) | 2009-02-12 | 2011-09-06 | Astellas Pharma Inc | Derivado de heteroanillo. |
| BRPI1013600A2 (pt) | 2009-03-27 | 2019-09-24 | Pathway Therapeutics Inc | "sulfonamidas de pirimidinila e benzintoazol de 1,3,5-triazinila e seu uso em terapia de câncer" |
| CA2763624A1 (en) | 2009-05-27 | 2010-12-02 | Abbott Laboratories | Pyrimidine inhibitors of kinase activity |
| US20110039873A1 (en) | 2009-06-08 | 2011-02-17 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| KR101903354B1 (ko) | 2009-06-17 | 2018-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| CA2987503C (en) | 2009-07-07 | 2019-02-26 | Mei Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| JP2012533551A (ja) | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | ピロロピラジン系キナーゼ阻害薬 |
| EP2454257B1 (en) | 2009-07-15 | 2013-08-21 | AbbVie Inc. | Pyrrolopyridine inhibitors of kinases |
| JP2011136925A (ja) * | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| ES2539170T3 (es) | 2010-01-12 | 2015-06-26 | Ab Science | Inhibidores de quinasas de oxazol |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| CA2807226A1 (en) * | 2010-08-19 | 2012-02-23 | F.Hoffmann-La Roche Ag | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
| PE20131377A1 (es) | 2010-09-13 | 2013-11-30 | Novartis Ag | Triazina-oxadiazoles |
| US20140088056A1 (en) * | 2010-09-28 | 2014-03-27 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| EP2796456A1 (en) * | 2010-12-09 | 2014-10-29 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
| IN2013MN01519A (OSRAM) | 2011-02-25 | 2015-06-12 | Yuhan Corp | |
| CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| TWI623531B (zh) | 2012-11-21 | 2018-05-11 | Ｐｔｃ治療公司 | 經取代反向嘧啶ｂｍｉ－１抑制劑 |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US20220185795A1 (en) * | 2019-03-11 | 2022-06-16 | Ptc Therapeutics, Inc. | Compound form having enhanced bioavailability and formulations thereof |
-
2013
- 2013-11-21 TW TW102142555A patent/TWI623531B/zh active
- 2013-11-21 KR KR1020157016184A patent/KR102275676B1/ko active Active
- 2013-11-21 WO PCT/US2013/071132 patent/WO2014081906A2/en not_active Ceased
- 2013-11-21 CN CN202010080540.0A patent/CN111423417B/zh active Active
- 2013-11-21 PE PE2015000665A patent/PE20151413A1/es unknown
- 2013-11-21 PT PT138573266T patent/PT2922828T/pt unknown
- 2013-11-21 ES ES13857326T patent/ES2821529T3/es active Active
- 2013-11-21 EA EA201890142A patent/EA035349B1/ru not_active IP Right Cessation
- 2013-11-21 AR ARP130104300A patent/AR093579A1/es active IP Right Grant
- 2013-11-21 CU CU2015000053A patent/CU24387B1/es unknown
- 2013-11-21 CN CN201380070973.6A patent/CN104918919A/zh active Pending
- 2013-11-21 HK HK16103069.2A patent/HK1215032A1/zh unknown
- 2013-11-21 MX MX2015006469A patent/MX385385B/es unknown
- 2013-11-21 NZ NZ70890913A patent/NZ708909A/en unknown
- 2013-11-21 DK DK13857326.6T patent/DK2922828T3/da active
- 2013-11-21 AU AU2013348009A patent/AU2013348009C1/en active Active
- 2013-11-21 NZ NZ74660713A patent/NZ746607A/en unknown
- 2013-11-21 SG SG11201503982XA patent/SG11201503982XA/en unknown
- 2013-11-21 BR BR112015011760-0A patent/BR112015011760B1/pt active IP Right Grant
- 2013-11-21 MA MA38208A patent/MA38208B1/fr unknown
- 2013-11-21 PL PL13857326T patent/PL2922828T3/pl unknown
- 2013-11-21 PH PH1/2015/501130A patent/PH12015501130B1/en unknown
- 2013-11-21 UA UAA201505533A patent/UA118094C2/uk unknown
- 2013-11-21 US US14/443,911 patent/US10428050B2/en active Active
- 2013-11-21 EA EA201590992A patent/EA031405B1/ru unknown
- 2013-11-21 JP JP2015544124A patent/JP6412503B2/ja active Active
- 2013-11-21 KR KR1020227035587A patent/KR20220143164A/ko not_active Ceased
- 2013-11-21 EP EP13857326.6A patent/EP2922828B1/en active Active
- 2013-11-21 SG SG10201600149VA patent/SG10201600149VA/en unknown
- 2013-11-21 KR KR1020217020963A patent/KR102356487B1/ko active Active
- 2013-11-21 CA CA2892045A patent/CA2892045C/en active Active
- 2013-11-21 KR KR1020227002513A patent/KR102455889B1/ko active Active
-
2015
- 2015-05-18 IL IL238871A patent/IL238871B/en active IP Right Grant
- 2015-05-20 CL CL2015001377A patent/CL2015001377A1/es unknown
- 2015-05-21 MX MX2021009892A patent/MX2021009892A/es unknown
- 2015-05-21 EC ECIEPI201519948A patent/ECSP15019948A/es unknown
- 2015-05-21 NI NI201500072A patent/NI201500072A/es unknown
- 2015-05-21 SA SA517381847A patent/SA517381847B1/ar unknown
- 2015-05-22 ZA ZA2015/03642A patent/ZA201503642B/en unknown
- 2015-06-05 CR CR20150294A patent/CR20150294A/es unknown
-
2018
- 2018-09-28 JP JP2018183173A patent/JP6617186B2/ja active Active
-
2019
- 2019-03-10 IL IL265253A patent/IL265253A/en unknown
- 2019-09-26 US US16/583,442 patent/US11180483B2/en not_active Expired - Fee Related
- 2019-11-11 JP JP2019203706A patent/JP6918898B2/ja active Active
-
2021
- 2021-11-10 US US17/523,480 patent/US20220064150A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2922828T3 (da) | 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer | |
| LT3026064T (lt) | Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6 | |
| DK3628670T3 (da) | Saltform til ezh2-hæmning | |
| DK3527263T3 (da) | Bipyrazolderivater som jak-inhibitorer | |
| EP2981535B8 (en) | Urea derivatives useful as kinase inhibitors | |
| DK3181567T3 (da) | Pyrazolopyrimidinforbindelser som kinasehæmmere | |
| IL223201A (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| HUE037645T2 (hu) | Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok | |
| LT3495367T (lt) | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai | |
| LT3406251T (lt) | Piruvatkinazės aktyvatoriai, skirti panaudoti terapijai | |
| IL237475A0 (en) | Pyrlotriazinone derivatives as pi3k inhibitors | |
| DK2741763T3 (da) | Sammensætning til kontrolleret ovariestimulering. | |
| EP2863748A4 (en) | 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN | |
| HUE042032T2 (hu) | Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak | |
| EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
| DK2912032T3 (da) | 4-carboxamido-isoindolinonderivater som selektive parp-1-hæmmere | |
| BR112015012877A2 (pt) | composto de fórmula, composição farmacêutica, uso do composto e método para o tratamento do câncer | |
| LT2812013T (lt) | Kompozicija, skirta džs gydymui | |
| ME02908B (me) | Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije | |
| DK2851075T3 (da) | Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat | |
| EP3024427A4 (en) | Derivatives of 2,2,6-trimethylcyclohexane-carboxylate | |
| DK2825589T3 (da) | Nor-hals-forbindelser som flammehæmmere | |
| TH1401005856A (th) | สารอนุพันธ์ไธอีโนไพริมิดีนชนิดใหม่, กระบวนการสำหรับการเตรียมของสารนั้น และ การใช้ในเชิงบำบัดของสารนั้น | |
| TH1301004215B (th) | องค์ประกอบเชิงเภสัชกรรมซึ่งประกอบรวมด้วยอนุพันธ์ไพริโอน |